VC005 tablets for severe alopecia areata, compared with placebo tablets
Tests VC005 tablets against placebo in adults with severe alopecia areata.
Key facts
- Who runs it
- Jiangsu vcare pharmaceutical technology co., LTD
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 18 Aug 2026
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Drug: VC005 tablets
- VC005 tablets
- VC005 placebo tablets
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe alopecia areata, a condition where hair falls out in patches. It tests VC005 tablets against a placebo (dummy tablet).
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Severe alopecia areata. People must meet the diagnostic criteria for alopecia areata at screening and at the start of the trial.
Main reasons for not taking part
- Pregnant or breastfeeding women, or people planning pregnancy or breastfeeding during the study
- Current acute diffuse alopecia areata
- Other types of hair loss that may affect the assessment, such as traction, scarring or androgenetic hair loss
- Other scalp diseases such as scalp psoriasis, dermatitis or tinea capitis (fungal scalp infection)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written informed consent by signing the informed consent form (ICF)
- Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender
- Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits
Who cannot take part
- Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc
- Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc
- Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period
- Subjects with a current diagnosis of acute diffuse alopecia areata (AA)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
The 3 groups in the trial
- VC005 Tablets Low Dose groupTreatment being tested
Treatment: Drug: VC005 tablets
- VC005 Tablets High Dose groupTreatment being tested
Treatment: VC005 tablets
- VC005 Tablets placebo groupPlacebo, for comparison
Treatment: VC005 placebo tablets
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata
- Plain-language title
- VC005 tablets for severe alopecia areata, compared with placebo tabletsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07749716, who can take part
- Record updated
- 27 August 2026